



ASX Announcement | 7 January 2020
Althea Group Holdings (ASX:AGH)

Althea exceeds year-end target of 4,000 patients with 48% month on month growth in Australia

Investment Highlights:

- 4,018 patients were prescribed Althea medicinal cannabis products in Australia as at 31 December 2019
- An average of 36 new patients were added each business day in December, up 48% from November 2019
- 432 Healthcare Professionals have now prescribed Althea medicinal cannabis

7 January 2020: **Australian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company')** is pleased to provide the following market update with regards to the uptake of its medicinal cannabis products in Australia as at year-end 2019.

4,000 patients target exceeded

Further to the Company's market update (17 December 2019) Althea confirms that as at 31 December 2019, 4,018 patients were prescribed Althea medicinal cannabis in Australia, exceeding the Company's target of 4,000 by year-end. The month on month growth rate has continued to accelerate with an average of 36 new patients added each business day in December 2019, up 48% from November 2019.

In addition, a total of 432 Australian Healthcare Professionals had prescribed Althea's products.

Chart 1: Patient Growth as at year-end 2019







Chart 2: HCP Growth as at year-end 2019



Althea CEO Josh Fegan said: “Mid-way through 2019 we set a target of 4,000 patients by the end of the year and by mid-December, we were well placed to reach it. Having received our final 2019 numbers, I am pleased to advise that Althea concluded the year by exceeding its target, with 4,018 patients prescribed our medicinal cannabis products. We now have our sights set on a strong 2020 where we once again expect to see significant patient and prescriber growth.”

-ENDS-

Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea
Josh Fegan
CEO & Managing Director
M: 1300 70 20 20
E: contact@althea.life

Media Enquiries
Kirby Symes
Media Relations
P: +613 9650 5096
E: ksymes@althea.life

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of products, education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.



Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into Germany, emerging markets throughout Asia and other parts of Europe.

To learn more, please visit: www.althea.life